Psychometric Properties of the Chinese Version of PeNAT
Launched by THE HONG KONG POLYTECHNIC UNIVERSITY · Mar 30, 2021
Trial Information
Current as of July 06, 2025
Unknown status
Keywords
ClinConnect Summary
Currently, the most effective anti-emetics appear to be 5-HT3 inhibitors, followed by NK1 inhibitors and neuroleptic drugs. Nevertheless, anti-emetics alone are not sufficient to manage these two symptoms. This poor symptom control could be due to healthcare professionals' perception that nausea and vomiting are solely biological problems, and their heavy reliance on pharmacological treatment for management. After literature search, we can identify only one validated instrument, the Pediatric Nausea Assessment tool (PeNAT), assessing chemotherapy-induced nausea and vomiting in children. Yet...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 4 - 17
- • A confirmed diagnosis of cancer
- • Currently undergoing chemotherapy
- • Able to speak Cantonese and read Chinese
- Exclusion Criteria:
- • Cognitive or behavioral problems in medical records
About The Hong Kong Polytechnic University
The Hong Kong Polytechnic University (PolyU) is a leading institution in applied research and education, dedicated to advancing knowledge and innovation in various fields, including health sciences. As a clinical trial sponsor, PolyU focuses on conducting rigorous and ethically sound research to enhance understanding of medical interventions and improve patient outcomes. The university leverages its multidisciplinary expertise, state-of-the-art facilities, and collaboration with industry partners to facilitate groundbreaking studies that address pressing health challenges. Committed to fostering an environment of academic excellence, PolyU aims to translate research findings into practical solutions that benefit society and contribute to the global advancement of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Katherine Lam, PhD
Principal Investigator
The Hong Kong Polytechnic University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials